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Case ReportHepatitis B virus DNA integration in tumour tissue of a non-cirrhotic
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Hospital of Modena, Modena, ItalyAbstract IntroductionCo-existence of multiple causes of liver injury increases the risk
of hepatocellular carcinoma (HCC) development. HCC usually
develops in patients with cirrhosis although it may also occur
in individuals with no or mild liver disease, in particular in cases
with hepatitis B virus (HBV) infection.
Here we report the case of a 43 year-old man with HFE-
haemochromatosis, seronegative for hepatitis B and C infections,
who developed HCC in the absence of severe liver damage. Both
tumoural and non-tumoural liver DNA extracts were tested by
nested-PCR and primers speciﬁc for four different HBV genomic
regions in order to evaluate the presence of occult HBV infection.
Only X gene sequences were detected in tumour (but not in non-
tumour) DNA extracts. HBV-Alu PCR showed a HBV integration
involving a 50-deleted X gene with an intact enhancer-II/basal-
core promoter region. The viral-host junction sequencing
revealed that this integrant was located upstream of the parti-
tioning-defective-6-homolog-gamma gene (PARD6G) and real
time-PCR quantiﬁcation demonstrated that PARD6G was overex-
pressed in tumour compared to non-tumour liver tissues.
In conclusion, the combination of HFE-haemochromatosis and
occult HBV infection in this patient might have led to a sequel of
cellular events that determined the development of HCC even in
the absence of cirrhosis.
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gamma gene.Hepatocellular carcinoma (HCC) is largely the most common
malignancy of the liver worldwide [1–3]. It may occur as a con-
sequence of every pathologic condition able to provoke chronic
liver damage, and cirrhosis is recognized to be a nodal step in
hepatocarcinogenesis. The risk of HCC development is strongly
increased by the co-existence of two or more causes of liver
injury, particularly when hepatitis B virus (HBV) is involved,
such as the case of HBV carriers chronically co-infected with
hepatitis C virus (HCV) or exposed to aﬂatoxin B1 [1–3]. Apart
from the long-lasting hepatitis produced by chronic infection,
HBV may exert a direct oncogenic role through several different
mechanisms, including viral DNA integration into the host gen-
ome as well as production of proteins with pro-oncogenic prop-
erties [1–3] and it may promote liver cell transformation and
cancer even independently of cirrhosis development [1]. More-
over, much evidence indicates that HBV may maintain its pro-
oncogenic role also in the case of occult infection, deﬁned as
the persistence of viral DNA at intrahepatic level despite the
absence of circulating HBV surface antigen (HBsAg) [1,2,4]. Here
we report and discuss the results of molecular analyses
performed on liver tissue specimens of a non-cirrhotic HBsAg
negative patient with HFE-haemochromatosis who developed
HCC.Case report
In 1990, a 43-year-old man was diagnosed with hereditary hae-
mochromatosis, based on biochemical, clinical and histological
criteria. Serum ferritin (SF) was 3990 ng/ml. He underwent ﬁrst
weekly phlebotomy, and, after one year, a twice year mainte-
nance treatment. The diagnosis was conﬁrmed in 1997 by HFE
gene sequencing that documented homozygosity for the
c.845G>A (p.C282Y) change of the HFE gene.
In February 2008, he was diagnosed with HCC by imaging
(two nodules of 2.5 cm and 3.6 cm each) and histology. SF was
240 ng/ml and all liver tests were normal. He was negative for
all serummarkers of HBV and HCV infection, although he showed
results of blood analyses performed in 1990 where he tested
positive for antibodies to HBV core antigen (anti-HBc). The HCC
nodules were treated by chemoembolization.13 vol. 58 j 190–193
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Fig. 1. Schematic representation of HBV DNA integration site. Shaded box, HBV
sequence. The region corresponding to the basic core promoter (BCP) and
enhancer II is indicated within the viral sequences by the ﬁlled black box.
Numbering of nucleotides is according to HBV ayw subtype. Open box, PARD6G
coding sequence. Bold arrowheads, orientation of the ORF. The distance between
the HBV integration site and the gene ATG is indicated (3.7 kb).
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In November 2009, the patient underwent orthotopic liver
transplantation (OLT) due to HCC recurrence. At present, the
patient is undergoing the planned post-OLT follow-up with no
evidence of HCC recurrence.
At the time of OLT, small portions of tumoural and non-
tumoural tissue specimens were collected and immediately
stored at 80 C for subsequent molecular investigations. The
non-tumoural liver tissue was histologically examined, showing
a preserved liver architecture, absence of signiﬁcant ﬁbrosis
and/or inﬂammatory inﬁltrates, minimal iron deposits.
The frozen liver specimens were divided into two parts and
total DNA and RNA were extracted from each of them. DNA
extracts were processed for investigating a possible occult
HBV infection through well established procedures [4]. The
non-tumoural liver specimen proved negative for all four dif-
ferent viral genomic sequences tested (S, Core, Pol, X genes),
while in the neoplastic tissue only the sequence corresponding
to the X gene proved positive, suggesting the possible presence
of viral DNA integration into the host genome. In order to test
this hypothesis, DNA extracts from both tumoural and non-
tumoural tissues were examined through HBV-Alu PCR
approach. Brieﬂy, DNA was extracted from the frozen liver
specimens by standard procedures. After the ﬁrst 10 cycles of
tag introducing ampliﬁcation, the Alu primers were destroyed
by UDG treatment, taking advantage of incorporated dUTPs in
the primers. HBV primers speciﬁc for core, X and S regions
[5] were used.
Ten pM of each primer was added for the next ampliﬁcation,
for which a ‘‘touchdown’’ PCR technique was applied. Five ll of
the ampliﬁed products was subjected to nested PCR with internal
speciﬁc HBV primers. PCR was performed using the Expand high-
ﬁdelity PCR system (Roche Diagnostics, Mannheim, Germany).
PCR products were separated by electrophoresis in a 1% agarose
gel and visualized by ethidium bromide staining. Southern blot
experiments were performed to show the speciﬁcity of the ampli-
ﬁcation products.
The HBV-Alu PCR approach made it possible to reveal inte-
grated HBV DNA in the host genome of the tumoural tissue, while
no viral integrants were detected in the non-neoplastic specimen.
The PCR products testing positive for HBV integration were those
obtained using HBV primers designed for the X region.
Nucleotide sequences of the PCR product containing the viral-
host junction were determined using nested PCR primers and the
BigDye Terminator Cycle Sequencing Ready Reaction Kit (Apple-
ra, Foster City, CA) according to the manufacturer’s instructions.
The sequencing products were resolved in an automatic DNA
sequencer (ABI PRISM 310 Genetic Analyzer; Applera). Nucleotide
sequences of HBV DNA were characterized through alignment
using the CLUSTAL W program. The cellular ﬂanking sequences
were assessed using the BLAST search system. This approach
allowed a complete characterization of the integration. The HBV
integrant was 384 nucleotides long (from nucleotide position
[nt] 1594 to nt 1978, numbering from the unique EcoRI site of
ayw subtype) and included a 50-terminal truncated X gene, the
precore region and 78 nt of the core gene. Therefore, the HBV
integrant comprised the basic core promoter (BCP)/enhancer-II
regulatory regions, the direct repeats DR-1 and DR-2, the unique
viral polyadenylation signal, as well as the HBV genomic
sequences corresponding to the second subelement of the post-
transcriptional regulatory element and the pgRNA encapsidation
signal e [2,6]. The viral integrant was located 3743 nucleotidesJournal of Hepatology 201upstream of the coding sequence for PARD6G, on chromosome
18. Orientation of the HBV genome open reading frame (ORF) is
the same as the cellular gene orientation (Fig. 1). Considering that
the BCP/enhancerII HBV sequence in the integration site could be
disruptive to normal cellular gene transcription, PARD6G gene
expression was assessed in the HCC specimen, in the correspond-
ing non-tumoural liver tissue and in normal liver tissue samples
from three liver-disease-free individuals (who undergone liver
resection or needle biopsy during abdominal surgery) used as
control, by a speciﬁc real time RT-PCR approach. Brieﬂy, tissue
specimens were homogenized by the use of TissueRupter
instrument (Qiagen, Milano, Italy) in 500 ll of TRIzol reagent
(Invitrogen, Paisley, Scotland) as recommended by the manufac-
turer. Samples containing equal amounts (5 lg) of total cellular
RNA were treated with RQ1 RNase-free DNase (Promega,
Madison, WI) for 1 h at 37 C and then used as template for
ﬁrst-strand cDNA synthesis with Super Script reverse transcrip-
tase (Invitrogen) and oligo(dT) primers. The cDNA samples were
then ampliﬁed in Master Mix buffer (Roche Diagnostics). The
sequences and nucleotide positions of the primers and probes
for PARD6 real-time PCR assay were as follows: PARD6G-F,
50-ACCAGCGCAACAACGT-30 (nt 918 to 933) PARD6G-R,
50-GTCGTTGTCCTCATCGCTC-30 (nt 1066 to 1048); PARD6G/FL (FRET
hybridization probe), 50-CGCGGCGGCCGCGCGTTGGGCA-FL-30 (nt
938 to 959); and PARD6G/LC (FRET hybridization probe), 50-LC-
ReD640-CGGGACCGCCCTCGGACGGCACC-PH-30 (nt 963 to 985).
Real-time PCR by use of the ‘‘utility channel’’ of a Cobas TaqMan
48 instrument was performed under the following conditions:
95 C for 10 min and then 60 cycles of 95 C for 30 s, 57 C for
20 s, and 72 C for 20 s. The plasmid pCRII-PAR6, containing one
copy of the PARD6G gene sequence (nt 163 to 1297), was used
as a standard for PARD6G cDNA quantiﬁcation. The plasmid was
digested with EcoRI (New England Biolabs GmbH, Frankfurt,
Germany), and the PARD6G sequence was gel puriﬁed using the
Wizard SV gel and PCR clean-up system (Promega, Madison,
WI). The concentration of puriﬁed PARD6G DNA was determined
with an ND-1000 spectrophotometer (Nano-Drop Technologies,
Wilmington, DE), and the corresponding copy number was
calculated. A series of 10-fold dilutions of the plasmid pCRII-
PAR6 was used as a standard for PARD6G cDNA quantiﬁcation.
The h-G6PDH housekeeping gene Light Cycler set (Roche Diagnos-
tics) was used to normalize the RNA samples. All experiments
were reproducible and were carried out in triplicate or
quadruplicate.
The results showed an overexpression of PARD6G in the
neoplastic tissue, compared to non-neoplastic and normal liver
samples where PARD6G expression was similar (Table 1).3 vol. 58 j 190–193 191
Table 1. Relative PARD6G mRNA levels in tumour and non-tumour liver tissue of the studied patient and in three different normal liver tissue specimens.
Tissue sample Tumour Non-tumour NL1 NL2 NL3
PARD6G (fold changes), mean ± SD 40 ± 6*§^# 0.22 ± 0.09*abc 0.07 ± 0.01§a 0.12 ± 0.08^b 0.08 ± 0.1#c
⁄p <0.0001; §p <0.0001; ^p <0.0001; #p <0.0001; ap = not signiﬁcant (n.s.); bp = n.s.; cp = n.s.
NL, normal liver; SD, standard deviation.
Student’s t test for paired samples was used to determine statistical signiﬁcance. Differences were considered statistically signiﬁcant at a p value 60.05.
Case ReportDiscussion
The case reported here presents several peculiar and conceptu-
ally intriguing aspects. First of all, HCC developed in the absence
of cirrhosis, an event generally infrequent, also in haemochroma-
tosis patients. Secondly, the patient had been positive for anti-
HBV antibodies in the past, but at the time of HCC diagnosis he
tested negative for all HBV serum markers. In addition, the
non-tumoral liver tissue was negative for all four different HBV
genomic sequences tested, thus apparently excluding a typical
occult HBV infection, which is deﬁned as the intrahepatic long-
lasting persistence of episomal viral DNA and recognized through
detection of at least two different viral genomic regions [7]. Fur-
thermore, no viral integrants were found in the non-neoplastic
specimen. On the contrary, the analysis of the tumour tissue
revealed the presence of HBV X gene sequences that were shown
to be integrated into the host genome once examined by Alu-PCR
technique. Altogether, these data suggest that HBV infection had
occurred but the virus was cleared from the liver, persisting
solely as DNA integrated into the genome of some hepatocytes
which subsequently expanded clonally as tumour cells.
The ability of HBV DNA to integrate in the host genome is con-
sidered to be a key event in HBV-related hepatocarcinogenesis.
HBV DNA integration occurs randomly in the context of the
human genome and may involve multiple sites of different chro-
mosomes [2,8,9]. Nevertheless, viral DNA very frequently inte-
grates near or within fragile sites or other repetitive regions of
the human genome as Alu sequences and microsatellites that
are prone to instability in tumour development and progression
[10].
There is evidence demonstrating that some conditions modi-
fying cellular homeostasis may increase the frequency of inser-
tional events. In particular, it has been shown that exposure to
oxidative stress may favour HBV DNA integration [8]; in the case
reported here it can be speculated that iron accumulation created
the conditions for HBV DNA integration through the continuous
oxidative stress determined in the hepatocytes.
Integrated HBV DNA might contribute to hepatocellular
malignant transformation either through the production of
mutated viral proteins such as truncated X- or preS/S-proteins,
which often possess transcriptional trans-activator properties
and are able to activate signalling pathways implicated in tumor-
igenesis [11–13], or through the insertion of viral DNA into cellu-
lar genomic regulatory regions or coding regions with
consequent modiﬁcation of gene expression or structural and
functional alteration of the produced cellular proteins [1,2,14].
This evidence has very recently been strongly strengthened by
a study in which a genomewide survey of HBV integration in liver
cancer genomes has shown that most HBV breakpoints in HCC
occur inside or near coding genes. Moreover, regardless of
whether HBV integration was at promoter, exon or intron, all
genes recurrently affected in the tumour samples show much192 Journal of Hepatology 201higher expression levels compared to the non-tumour samples
[9].
In the case reported here, an activation of PARD6G expression
is demonstrated by the real-time PCR ﬁndings, showing a strong
overexpression of PARD6G transcripts in the neoplastic tissue
compared to the non-neoplastic specimen as well as to normal
control liver tissues. HBV integrant could have had a key role in
the upregulation of PARD6G expression since the viral sequence
integrated in proximity of the PARD6G open reading frame con-
tains the enhancer II/BCP HBV regulatory region. The deregula-
tion of PARD6G expression is of particular relevance since it
encodes for a protein that is part of the Par6 complex, which is
involved in the establishment of cell polarization and in the
polarized migration of cells [15]. The Par6 complex binds to atyp-
ical protein kinase C (aPKC) and to a Rho family GTPase, RacI, that
is a critical downstream effector of oncogenic PKCi in multiple
cell types [16]. Furthermore, Par6 is a target of the transforming
growth factor-beta (TGFb) and mediates TGFb-induced epithelial-
to-mesenchymal transition (EMT), a process very likely responsi-
ble for tumour invasion and metastasis, as recently demonstrated
in breast cancer [17].
In conclusion, in the case reported here a sequence of virolog-
ical and cellular events probably led to the development of HCC
even in the absence of cirrhosis. It is likely that an occult HBV
infection had occurred in this patient, and that the continuous
cellular oxidative stress determined by iron accumulation in
the hepatocytes had favoured the integration of viral genomic
sequences into cellular DNA, which persisted in the liver after
the clearance of the virus. The peculiar site of cellular integration
and the presence of cis-regulatory elements in the integrated
viral sequences might have promoted mechanisms leading to a
deregulation of PARD6G expression and to the alteration of onco-
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